HC Wainwright Analysts Lift Earnings Estimates for NovoCure

NovoCure Limited (NASDAQ:NVCR) – Stock analysts at HC Wainwright upped their Q1 2026 earnings estimates for shares of NovoCure in a research report issued to clients and investors on Thursday, February 26th. HC Wainwright analyst E. Bodnar now anticipates that the medical equipment provider will earn ($0.36) per share for the quarter, up from their previous estimate of ($0.54). HC Wainwright currently has a “Buy” rating and a $49.00 price target on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for NovoCure’s Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.15) EPS, FY2027 earnings at ($0.62) EPS, FY2028 earnings at $0.49 EPS, FY2029 earnings at $2.45 EPS and FY2030 earnings at $4.79 EPS.

Several other analysts have also issued reports on NVCR. Evercore set a $20.00 price target on shares of NovoCure in a research report on Monday, January 5th. Weiss Ratings restated a “sell (e+)” rating on shares of NovoCure in a research note on Thursday, January 22nd. Finally, Wedbush restated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a research report on Thursday, January 15th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $26.93.

NovoCure Stock Performance

NVCR opened at $13.67 on Monday. The stock’s 50 day moving average price is $12.73 and its two-hundred day moving average price is $12.67. The firm has a market capitalization of $1.56 billion, a P/E ratio of -11.20 and a beta of 0.71. The company has a quick ratio of 1.50, a current ratio of 1.55 and a debt-to-equity ratio of 0.57. NovoCure has a 12-month low of $9.82 and a 12-month high of $21.55.

NovoCure (NASDAQ:NVCR) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.19. The firm had revenue of $174.35 million for the quarter, compared to the consensus estimate of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 38.82%. The business’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.61) EPS.

Institutional Trading of NovoCure

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Kera Capital Partners Inc. increased its position in shares of NovoCure by 84.4% in the 4th quarter. Kera Capital Partners Inc. now owns 19,691 shares of the medical equipment provider’s stock valued at $244,000 after buying an additional 9,015 shares in the last quarter. Corient Private Wealth LLC lifted its position in shares of NovoCure by 178.0% in the fourth quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider’s stock worth $1,259,000 after purchasing an additional 62,341 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in shares of NovoCure by 14.5% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock worth $422,000 after buying an additional 4,124 shares during the last quarter. Empowered Funds LLC bought a new position in shares of NovoCure during the 4th quarter worth approximately $33,000. Finally, XTX Topco Ltd increased its holdings in shares of NovoCure by 159.2% during the 4th quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock worth $760,000 after acquiring an additional 36,111 shares during the last quarter. 84.61% of the stock is owned by institutional investors.

Key Headlines Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (loss of $0.22 vs. est. -$0.41) and revenue was essentially in line, with revenue up ~8% year‑over‑year — evidence of top‑line momentum as the company scales. Article Title
• Positive Sentiment: Management raised FY‑2026 revenue guidance to $675M–$705M, above consensus (~$670M), which supports revenue growth expectations for the year ahead. Article Title
• Positive Sentiment: HC Wainwright increased its price target (to $49) and maintained a Buy rating — a bullish analyst call that could support investor interest given the large implied upside vs. current levels. Article Title
• Neutral Sentiment: Analyst coverage is mixed but active — a recent Benzinga deep dive summarizes four analyst viewpoints, useful for gauging near‑term sentiment and differential expectations. Article Title
• Neutral Sentiment: The full earnings call transcript and slide deck are available — management discussed strategic growth initiatives (market expansion and commercial execution), which investors should review for details on cadence and investments. Article Title
• Negative Sentiment: Despite revenue growth and beats, NovoCure remains loss‑making with a negative net margin (~27.7%) and negative ROE; analysts still model a negative EPS for the year, keeping valuation and profitability concerns front‑of‑mind. Article Title
• Negative Sentiment: Management flagged operational challenges on the call (execution and other near‑term issues), which could constrain margin improvement and near‑term cash flow conversion. Article Title

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.